Introduction
============

According to the Annual Report on the Aging Society 2015 from the cabinet office of the Japan government, ^[@B1]^ the aged (65 y.o. or older) population in Japan is approximately 33,920,000 in 2015, as its percentage against whole population is 26.7%. It is predicted that the aged population will rise to reach its peak as 39,000,000 in 2040. The rate of aged population will rise afterwards to reach to its peak as 40% in 2060.

As aged population increase, instances of traumatic brain injury (TBI) in the elderly are increasing. It has been known that the frequency curve of TBI by age groups has two peaks, as both 15--29 and 65--79 y.o. ^[@B2]^ In recent years, it is going to have a single peak only at the elderly generation, resulting from both decreased frequency in the young and increased frequency in the elderly. ^[@B3]^ In addition, the peak of frequency in the elderly is going to shift to older. ^[@B4]^ Such changes may be resulted from population aging, as well as recent reduction in traffic injury.

In general, prognostic factors of TBI includes prior history of medical illness, multiple traumatic injuries, severity of injury, mechanism of injury, clinical severity such as Glasgow Coma Scale (GCS) score, pupillary response, hypoxia, hypotension, and so on. Age has been proposed as one of the most reliable prognostic factors following TBI. ^[@B5]^ Both survival and functional outcome are significantly poorer in the elderly compared to the younger patients with TBI. It has been also reported that the duration of hospital stay is significantly longer in the elderly than younger patients with TBI. ^[@B6]^ According to Japan Neurotrauma Data Bank (JNTDB), it has been reported that the mortality seems to decrease in the elderly with TBI, without increase of favorable functional outcome. ^[@B4]^ The increase of elderly patients with TBI may require the increase of medical, rehabilitation, and nursing care resources. Thus, it is an urgent and an important issue to establish preventions and treatments of elderly TBI for Japan as well as other developing countries, which are facing both falling birthrates and aging societies.

In this article, both the clinical characteristics and the problems of TBI in the elderly, including delayed deterioration or the influences of either anti-coagulant or anti-platelet, are reviewed to make reference to the management strategy and the outcome.

Clinical Characteristics and Problems of TBI in the Elderly
===========================================================

Characteristics and problems of physical function in the elderly
----------------------------------------------------------------

As the cause of TBI, falls to the ground either from standing or from heights are the most common causes of TBI in the elderly, whereas the traffic accident is less common. ^[@B7]^ The cause of falls may be closely associated with the deterioration of physical functions, including visual, auditory, and equilibrium functions. The weakened muscle strength or the articular diseases may be also included, as well as cognitive dysfunction by dementia, faint, cardiac hypofunction, orthostatic hypotension, hemiparesis resulting from stroke, anemia, hypoglycemia, dehydration, body temperature elevation due to systemic infections. In addition, certain drugs have been identified as "fall risk-increasing drugs", such as opioids, antipsychotics, anxiolytics, hypnotics, sedatives, and antidepressants. Drugs, which may cause or worsen orthostatism, may also modify to increase the risk of fall, such as vasodilators used in cardiac diseases, antihypertensives, diuretics, beta blocking agents, calcium channel blockers, renin-angiotensin system inhibitors, alpha-adrenoreceptor antagonists, dopaminergic agents, and so on. ^[@B8]^ In certain situations, it is important that treatments for either such causes of trauma or backgraound diseases may be given priority for the management of TBI in the elderly.

Pedestrian accidents are significantly more common in the elderly than the young, as the second common next to falls. They account for 13% of the TBI mechanisms in the elderly, being high risk for severe TBI. ^[@B9]^ Impaired cognitive function, such as either concentration or reaction, may be associated with the mechanisms of injury, as well as deterioration of physical and physiological functions.

Morphological characteristics and pathophysiology
-------------------------------------------------

Morphologically, distribution of traumatic intracranial lesion is different by age groups. Diffuse injury is less common in the elderly than the young. In contrast, focal injury is more common in the elderly. ^[@B10]--[@B12]^ It is well known that the subdural, contusional, and intracerebral hematomas are more common TBI lesions in the elderly than the young, although epidural hematomas are less common in the elderly. Those characteristics of intracranial lesion have been explained by morphological changes due to aging. It has been reported that whole brain volume increases during childhood, and reaches to its peak during young adulthood between 18 and 35 years of age. Whole brain volume then decreases gradually after 35 years of age, as 0.2--0.5% per year. Approximately, 6--11% of brain volume reduction occurs by 60--80 years of age. ^[@B13]^

As the brain volume decreases in the elderly, the volume of subdural space increases as well as the mobility of the cerebral hemisphere. In addition to the fragility of the vascular wall structure by aging, since bridging veins adhere to the dura mater or to the brain surface firmly, bridging veins may be at risk to be injured by cerebral hemisphere mobilization by trauma, resulting in subdural hematomas. Increase of cerebral hemispheric mobility may also cause contre-coup injury. The fragility of cerebral vessels by aging may cause intracerebral hematomas in the elderly. In contrast, epidural hematomas rarely occur in the elderly, since the dura mater adheres inner surface of the cranium.

Interhemispheric subdural hematoma (iSDH) is a rare but a typical clinical entity with which the increased volume of the subdural space is closely associated ([Fig. 1](#F1){ref-type="fig"}). It typically occurs in the elderly by the injury of bridging veins which flow into the superior sagittal or the straight sinuses. The amount of the iSDH is usually small to be expected spontaneous healing in most cases. Some cases with a large amount of iSDH often represents falx syndrome, which typically show contralateral hemiparesis or monoparesis of lower extremity. The iSDH is commonly appear at parietal and occipital region, and rarely complicated with skull fractures. ^[@B14],[@B15]^

Physiological characteristics and the influences of systemic complication
-------------------------------------------------------------------------

From the view point of cerebral blood flow (CBF) and metabolism, CBF at cerebral cortex decreases by aging, although subcortical CBF is not significantly affected by age. ^[@B16],[@B17]^ Cerebral arterial autoregulation is impaired in the elderly, as well as vasoreactivity to either pCO ~2~ or metabolic changes. ^[@B18],[@B19]^ In addition, since the tolerance to ischemia is impaired by aging, the elderly has been postulated to be vulnerable to reduced CBF and metabolism after TBI.

CBF reduction during the first several hours after TBI ^[@B20],[@B21]^ may be brought by cerebral perfusion pressure (CPP) decrease due to the elevation of intracranial pressure (ICP), cerebral vasospasm, and dysautoregulation of cerebral arteries. Thus, either ICP or CPP oriented management has been thought to be important for TBI, to avoid secondary ischemic injury. Since autoreguation of cerebral vessels are impaired in elderly patients with TBI in general, CPP management may be more suitable to be oriented.

Hyperemia/hyperperfusion may occur subsequent to several hours period of cerebral hypoperfusion. ^[@B20]--[@B22]^ Since hyperemia/hyperperfusion is often prolonged and closely associated with poor outcome, reperfusion injury may play some roles in delayed deterioration. ^[@B23]^ Early induction of mild hypothermia has been reported to be useful for the management of traumatic intracranial hematoma. ^[@B24]^ Thus, mild hypothermia may have a potential as a treatment option for reperfusion injury induced by hyperemia/hyperperfusion in TBI. However, it has been reported that hypothermia failed to improve outcome in patients over 45 years of age with TBI, ^[@B25]^ suggesting that an optimal treatment strategy has not been established yet.

From the aspect of systemic physiological function, subclinical cardio-pulmonary dysfunction by aging reduces systemic physiological reserve capacity as well as tolerance to traumatic stress, leading to secondary traumatic injury. For example, subclinical pulmonary dysfunction easily induces hypoxia in the elderly with TBI. ^[@B26],[@B27]^ Subclinical cardiac dysfunction limits safety range of treatment between hypovolemia and volume overload. ^[@B28]^ In addition, pathophysiological conditions after TBI may be harmfully influenced by certain systemic complications such as malignant tumors, renal dysfunction, liver diseases, cardiac diseases, chronic obstructive pulmonary diseases, and so on. ^[@B29],[@B30]^ These systemic physiological dysfunction, even subclinical, may harmfully influence on the outcome in the elderly cases with not only severe but also mild to moderate TBI.

Delayed deterioration in the elderly
------------------------------------

Survival curve after TBI by age groups seems interesting, ^[@B6]^ as the elderly patients show a markedly different trend in comparison with other age groups. Death within 48 hours of admission is not different among all age groups. After then, only the elderly group shows a progressive decrease in survival until the rate leveled off at approximately 35%, whereas the other age groups tend to level off at approximately 60--80% survival. ^[@B6]^ These results suggest that delayed deterioration may be an important cause of poor outcome in the elderly with TBI.

Delayed deterioration, so-called "talk and deteriorate (T&D)", is defined as a patient who represent a relatively good neurological condition during the first certain period after head injury, and then deteriorate to a severe neurological condition (e.g. Glasgow Coma Scale score of 8 or less) within 48 hours of injury. It is more common in the elderly than young, and has been proposed as occurring in 20--30% of the elderly patients with TBI. T&D is often induced by delayed hyperemia/hyperperfusion, delayed traumatic intracerebral hematoma, delayed expansion of subdural hematoma, or delayed aggravation of traumatic contusional edema. The enlarged subdural space, which buffers ICP elevation, may delay to represent clinical deterioration in the elderly. In addition, cognitive disorders such as dementia can also delay the detection of neurological deterioration in the elderly.

Delayed deterioration is the most common in elderly cases with cerebral contusion. ^[@B31],[@B32]^ Cerebral contusional edema has been classified as early massive edema and delayed-pericontusional edema. ^[@B33]^ The early massive edema is defined as a hypointensity core on diffusion-weighted magnetic resonance image (MRI), which appears within 24 hours after TBI, suggesting that intra-and extracellular components undergo disintegration and homogenization in the central area of the contusion. In contrast, delayed-pericontusional edema is defined as predominant cellular swelling in the peripheral area. There is a crescent-shaped border zone of very high acquisition diffusion coefficient value on MRI between these central and peripheral area. ^[@B33],[@B34]^ In spite of CBF reduction, edema fluid is supplied excessively in the area of the cerebral contusion. In addition, hyperemia/hyperperfusion subsequent to ischemia enhances contusional edema aggravation, resulting in delayed deterioration.

Delayed traumatic intracerebral hematoma ([Fig. 2](#F2){ref-type="fig"}) and delayed expansion of either traumatic acute subdural hematoma ([Fig. 3](#F3){ref-type="fig"}) or intracerebral hematoma ([Fig. 4](#F4){ref-type="fig"}) may be other important clinical entities for delayed deterioration. Either of them may delay to represent clinical neurological deterioration, since the expansion of hematomas can be masked by the buffering effect of enlarged subdural space. In addition, the intracranial tissue compliance is declined in the elderly. ^[@B35]^ Thus, the delayed deterioration is rapidly progressive when enlarged hematomas exceed the intracranial buffering capacity.

As a unique entity of delayed deterioration after TBI, "delayed posttraumatic acute subdural hematoma (DASH)" in elderly patients on anticoagulation has been reported. ^[@B36]^ DASH has been defined as an acute subdural hematoma that is not apparent on the initial computed tomography (CT), and appears on a follow-up CT after 9 to 72 hours after TBI. ^[@B36],[@B37]^ Thus, DASH should be suspected in elderly, anticoagulated, mild TBI patients including those who present with Glasgow Coma Scale Scores of 15, and normal initial CT. It has been suggested that elderly anticoagulated mild TBI patients should be admitted for 24 to 48 hours of observation after injury.

Influences of anticoagulants and antiplatelets
----------------------------------------------

Anticoagulants, such as warfarin, has been widely used to prevent thrombo-embolisms in patients with atrial fibrillation, prosthetic cardiac valve replacement, or deep venous thrombosis, and so on. In recent years, warfarin has been replaced by novel direct anticoagulants (DOACs) in a certain extent of cases, since DOACs do not require routine monitoring and reduce hemorrhagic complication compared with warfarin. Antiplatelets, such as aspirin, cilostazol, and clopidogrel, have been widely used to prevent thrombo-embolisms in patients with ischemic heart disease, ischemic stroke, arteriosclerosis obliterans, and so on. Patients, who have a history of thrombo-embolic disease mentioned above, are basically at a risk of either falls or traffic accidents. ^[@B38],[@B39]^ Although there are a few reports that neither anticoagulant nor antiplatelet influence on the mortality and morbidity in patients with TBI, ^[@B40]--[@B42]^ most of the available data suggest that a pre-injury reception of either anticoagulant or antiplatelet agent increases the risk of poor outcome in patients with TBI, mainly resulting from larger or repeated intracranial hematoma. ^[@B43]--[@B52]^ It has been also reported that the history of anticoagulant is closely associated with the occurrence of talk and deteriorate. ^[@B53]^

Therefore, in patients who receive pre-injury antiplatelet or anticoagulant therapy, discontinuation and/or reversal of these drugs should be considered after TBI, especially in cases with traumatic intracranial hematomas. [Table 1](#T1){ref-type="table"} summarizes available anti-platelets and anti-coagulant and their reversal agents ([Table 1](#T1){ref-type="table"}). Careful consideration is necessary to determine discontinuation and/or reversal of these drugs, since the risk for thrombo-embolism is different in each patient or background diseases.

For example, in cases with coronary stent implantation, the risk of life-threatening stent thrombosis is increased 30-fold if clopidogrel is discontinued within the first 30 days.^[@B54]^ Discontinuation of clopidogrel within the first 6-months is an independent determinant of stent thrombosis.^[@B55]^ It has been also reported that the cardiac complication rate is threefold increased after aspirin withdrawal.^[@B56]^ In patients who require surgery, it has been demonstrated that the risk of coronary thrombosis after discontinuation of antiplatelet is greater than the risk of surgical bleeding if antiplatelet is continued.^[@B57]^ "Bridging therapy" with heparin has been reported as ineffective in reducing cardiac events after withdrawal of antiplatelet therapy in patients with cardiac stents.^[@B58]^

As another example, preinjury use of warfarin seems to increase mortality in elderly patients regardless of injury severity.^[@B59]^ The admitted prothrombin time-international normalized ratio (PT-INR) is directly correlated with mortality.^[@B49]^ Specific replacement therapy, including vitamin K, fresh frozen plasma, or VII factor, facilitates successful clot evacuation without bleeding complications.^[@B60]^ Discontinuation of warfarin has been reported as approximately 5--6% per year risk of thromboembolism in cases with non-valver atrial fibrillation.^[@B61]^

Regarding DOACs, it has been reported that they are associated with lower mortality in patients with traumatic intracranial hemorrhage.^[@B62]^ However, reversal agents have not been established in most of DOACs except dabigatran ([Table 1](#T1){ref-type="table"}). In addition, both benefits and disadvantages have not been well known regarding discontinuation and/or reversal of DOACs in elderly cases with TBI.

Therefore, whether to discontinue anti-coagulant/-platelet therapy or not in patients with TBI may be decisions that depend on a variety of circumstances, such as the evidence mentioned above, the extent of the traumatic intracranial hematoma, and the indication for pre-injury use of anti-coagulant/-platelet agents. Currently, both risks and benefits, which are brought by discontinuation and/or reversal of either one of the anticoagulant or antiplatelet, should be carefully considered in each case.^[@B63]^

Establishment of management strategy
------------------------------------

As described above, the characteristics of the elderly with TBI suggest certain ideal strategies for the management. For example, the elderly with TBI may be easily affected by hypoxia or hypotension, since cardio-pulmonary reserve capacity is limited in the elderly. Shortening of either rescue or transfer time may be required to minimize harmful effect of hypoxia or hypotension, prehospitally. Careful assessment and/or monitoring of systemic condition may be also required for adequate cardio-pulmonary management, such as physiological monitoring including electrocaridogram, blood pressure, pulse-oxymetry, repeated blood-gas analyses, and so on. Since delayed deterioration seems closely correlated with outcome, early detection or prediction of delayed intracranial changes may be also important. To achieve it, monitoring of ICP, CPP, or other intracranial physiological variables may be important, as well as repeated careful neurological inspection and CT examination. In general, since the elderly may be risky for both general anesthesia and craniotomy, a less invasive procedure such as endoscopic acute subdural hematoma (ASDH) evacuation may be an ideal tool to minimize surgical complication. ^[@B64]^

In Guidelines for the Management of Severe Head Injury 3rd Edition, edited by the Japan Society of Neurotraumatology in 2013, the following recommendations are stated as experts' opinion regarding elderly with TBI; (1) prehospital care, initial treatment, and ICU management are equivalent to those for general adults, (2) strict and repeated neurological inspection is desirable to detect "talk and deteriorate", (3) systemic complications should be optimally treated, (4) both early induction and extended period of rehabilitation are desirable, since functional recovery after TBI often takes longer in the elderly, (5) surgical indications for the elderly are equivalent to those for general adults, although they should be carefully applied. ^[@B65]^ Such evidence-based guidelines for TBI have not stated any specific recommendation to the elderly, regarding prehospital care, primary management, or either one of timing, indications, or techniques of surgical management, despite age has been identified as a reliable independent prognostic factor for TBI. Prospective trial will be necessary to clarify evidences regarding those in future.
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![Interhemispheric subdural hematoma (iSDH).](nmc-57-418-g1){#F1}

![Delayed traumatic intracerebral hematoma. Note: (A) A falco-tentorial and convexity acute subdural hematoma (ASDH) was evident on CT at 1 hour after trauma. (B) The ASDH thickened slightly at 6 hours after trauma. An additional subcortical intracerebral hematoma appeared at right posterior-temporal area.](nmc-57-418-g2){#F2}

![Delayed expansion of ASDH. Note: (A) A thin ASDH was evident on CT at 1 hour after trauma. (B) The hematoma thickened at 6 hours after trauma.](nmc-57-418-g3){#F3}

![Delayed expansion of traumatic intracerebral hematoma. Note: (A) Only a thin ASDH was evident on CT at 1 hour after trauma. (B) A small contusional hematoma appeared at 24 hours after trauma, although the initial ASDH was mostly washed out. (C) The contusional hematoma was fused and enlarged at 48 hours after trauma.](nmc-57-418-g4){#F4}

###### 

Anti-platelet/-coagulant and potential reversal agents

  Medication                 Mechanism of action                                             Duration of effect                                   Potential reversal agents
  -------------------------- --------------------------------------------------------------- ---------------------------------------------------- ---------------------------------
  Aspirin                    Irreversible COX-1 inhibition                                   \> 36 hrs until 20% baseline after discontinuation   Platelets, desmopressin, rFVIIa
  Clopidogrel, Ticlopidine   Platelet ADP receptor (P2Y12) antagonist                        5 days to baseline after discontinuation             Platelets, desmopressin, rFVIIa
  Cilostazol                 PDE-III inhibitor                                               48 hrs to baseline after discontinuation             Platelets, desmopressin
  Warfarin                   Inhibit vitamin K dependent clotting factors (II, VII, IX, X)   48--72 hrs to baseline after discontinuation         Vitamin K, FFP, rFVIIa
  Dabigatran                 Thrombin inhibitor                                                                                                   Idarucizumab
  Rivaroxaban                Factor Xa inhibitor                                             24 hr                                                --
  Apixaban                   Factor Xa inhibitor                                                                                                  --
  Edoxaban                   Factor Xa inhibitor                                             24 hr                                                --
